Journal Article

Immunoproteasome inhibition attenuates experimental psoriasis

del Rio Oliva, Marta, Basler, Michael, Mellett, Mark

2022

Overview

Psoriasis is an autoimmune skin disease associated with multiple comorbidities. The immunoproteasome is a special form of the proteasome expressed in cells of hematopoietic origin. The therapeutic use of ONX 0914, a selective inhibitor of the immunoproteasome, was investigated in mice, which spontaneously develop psoriasis-like symptoms, and in the imiquimod murine model. In both models, treatment with ONX 0914 significantly reduced skin thickness, inflammation scores, and pathological lesions in the analyzed skin tissue. Furthermore, immunoproteasome inhibition normalized the expression of several pro-inflammatory genes in the ear and significantly reduced the inflammatory infiltrate, accompanied by a significant alteration in the αβ and γδ T cell subsets. ONX 0914 ameliorated psoriasis-like symptoms in two different murine psoriasis models, which supports the use of immunoproteasome inhibitors as a therapeutic treatment in psoriasis.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Animal models / Animals / Autoimmune Diseases / CARD14 / Comorbidity / Cytokines / Cytotoxicity / Flow cytometry / Imiquimod / Immunology / immunoproteasome inhibition / Inflammation / Inflammation - pathology / Laboratories / Lesions / Lymphatic system / Lymphocytes T / Mice / Normal distribution / ONX 0914 / Pathogenesis / Proteasome Inhibitors - pharmacology / Proteasome Inhibitors - therapeutic use / Proteasomes / Psoriasis / Psoriasis - drug therapy / Skin - pathology / Skin diseases